Corporate Interviews & Videos
September 22, 2025
Geert Kersten, CEO of CEL-SCI, discusses the innovative approach of using immunotherapy, specifically Multikine, in cancer treatment. He emphasizes the importance of the immune system in fighting cancer and the need for a paradigm shift in how cancer therapies are developed and administered.
September 9, 2025
An exclusive interview with Geert Kersten, CEO of CEL-SCI Corporation (NYSE American: CVM). Discover how CEL-SCI is advancing its lead immunotherapy, Multikine, through breakthrough regulatory pathways in both the U.S. and Saudi Arabia, while strengthening its financial and strategic position.
March 3, 2025
Geert Kersten discusses how CEL-SCI is taking a critical step forward in the fight against head and neck cancer with the initiation of the Multikine Confirmatory Phase 3 Trial—a pivotal study that could bring this innovative immunotherapy one step closer to FDA approval and commercialization.
November 22, 2024
Geert Kersten discusses the implications of the FDA’s Oncologic Drugs Advisory Committee (ODAC) decision on checkpoint inhibitors for patients with low or negative PD-L1 expression and the significance to CEL-SCI.
October 21, 2024
An interview with Geert Kersten discussing the unique approach CEL-SCI has to fight cancer.
October 23, 2023
A presentation delivered by Geert Kersten Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals.
September 2022
An oral presentation delivered by Dr. Philip Lavin of groundbreaking tumor response and increased overall survival in head and neck cancer. This presentation includes data presented at the European Society for Medical Oncology (ESMO) Annual Congress in September 2022.
September 9, 2025
An exclusive interview with Geert Kersten, CEO of CEL-SCI Corporation (NYSE American: CVM). Discover how CEL-SCI is advancing its lead immunotherapy, Multikine, through breakthrough regulatory pathways in both the U.S. and Saudi Arabia, while strengthening its financial and strategic position.
[corporate]